• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Dosing antipsychotics in special populations of patients with schizophrenia: Severe psychotic agitation, first psychotic episode and elderly patients
Expert Opin Pharmacother. 2021 Aug 2. doi: 10.1080/14656566.2021.1958781. Online ahead of print.ABSTRACTIntroduction: Antipsychotic (AP) dosing is well established in nonelderly patients with acute exacerbations of schizophrenia, but not in special populations.Areas covered: This review describes the AP dosing procedures that have been used in clinical studies for acute psychotic agitation, a first episode of psychosis (FEP), and elderly patients. AP dosing data was extracted from the databases of drug regulatory authorities, and from clinical studies available in the medical literature.Expert opinion: In acute psychotic a...
Source: Expert Opinion on Pharmacotherapy - August 2, 2021 Category: Drugs & Pharmacology Authors: Fay çal Mouaffak Florian Ferreri Julie Bourgin-Duchesnay Emmanuelle Baloche Olivier Blin Pierre Vandel Ricardo P Garay Pierre Vidailhet Emmanuelle Corruble Pierre-Michel Llorca Source Type: research

The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer ’s Disease
According to the World Alzheimer’s report, dementia was estimated to affect 50 million worldwide in 2018, number expected to increase to more than 150 million within 30 years. Alzheimer’s disease is the most common type of dementia, accounting on its own for 2/3 of all dementia cases. The initial signs and symptoms of Alzheimer’s disease relate to progressive cognitive decline, inexorably progressing until the loss of independence. Neuropsychiatric and behavioral symptoms may occur during the progression of the disease; around 20% of patients without any behavioral symptoms at the diagnosis will experience some of th...
Source: Frontiers in Pharmacology - December 5, 2019 Category: Drugs & Pharmacology Source Type: research

CNS Summit 2016 Abstracts of Poster Presentations
Conclusion: Subjects with acutely exacerbated schizophrenia who were eligible for discharge from the inpatient setting and who completed the study demonstrated high rates of adherence using the mobile AI application. Subjects were able to easily use the technology. Use of the platform did not appear to increase the dropout rate. This study demonstrates the feasibility of using AI platforms to ensure high adherence, provide reliable adherence data, and rapidly detect nonadherence in CNS trials. Disclosures/funding: Adam Hanina and Laura Shafner are employees of AiCure, New York, New York, and consultants to Takeda. Xinxin D...
Source: Innovations in Clinical Neuroscience - February 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Devices Drug Development Evaluations Genetics Medical Issues Neurology Patient Assessment Proceedings Psychiatry Psychopharmacology Scales Supplements Technology Trial M Source Type: research

Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients.
CONCLUSIONS: Only anti-inflammatory medications increased mortality risk with risperidone. The reduced risks of CVAE in patients with comorbid depression and delusions, and of mortality with depression, may have clinical implications when weighing the benefits and risks of treatment with risperidone in patients with dementia. PMID: 27388570 [PubMed - in process]
Source: The British Journal of Psychiatry for Mental Science - November 3, 2016 Category: Psychiatry Tags: Br J Psychiatry Source Type: research

Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients Review articles
Conclusions Only anti-inflammatory medications increased mortality risk with risperidone. The reduced risks of CVAE in patients with comorbid depression and delusions, and of mortality with depression, may have clinical implications when weighing the benefits and risks of treatment with risperidone in patients with dementia.
Source: The British Journal of Psychiatry - October 31, 2016 Category: Psychiatry Authors: Howard, R., Costafreda, S. G., Karcher, K., Coppola, D., Berlin, J. A., Hough, D. Tags: Review articles Source Type: research

Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients.
CONCLUSIONS: Only anti-inflammatory medications increased mortality risk with risperidone. The reduced risks of CVAE in patients with comorbid depression and delusions, and of mortality with depression, may have clinical implications when weighing the benefits and risks of treatment with risperidone in patients with dementia. PMID: 27388570 [PubMed - as supplied by publisher]
Source: The British Journal of Psychiatry for Mental Science - July 9, 2016 Category: Psychiatry Tags: Br J Psychiatry Source Type: research

Using Big data for an Economic Evaluation of reducing the Innappropriate prescribing of atypical Antipsychotics among Dementia Patients
This study is an economic evaluation of the NPS MedicineWise educational program in terms of reduced falls and stroke incidence due to reduction in antipsychotic prescribing including olanzapine, quetiapine and risperidone
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: R. Khan, A. Jammali-Blasi, A. Todkar, A. Heaney Source Type: research